Classification and Differential Diagnosis of Wilson's Disease
Overview
Authors
Affiliations
Wilson's disease is characterized by hepatic and extrapyramidal movement disorders (EPS) with variable manifestation primarily between age 5 and 45. This variability often makes an early diagnosis difficult. A classification defines different clinical variants of Wilson's disease, which enables classifying the current clinical findings and making an early tentative diagnosis. Until the unequivocal proof or an autosomal recessive disorder of the hepatic copper transporter ATP7B has been ruled out, differential diagnoses have to be examined. Laboratory-chemical parameters of copper metabolism can both be deviations from the norm not related to the disease as well as other copper metabolism disorders besides Wilson's disease. In addition to known diseases such as Menkes disease, occipital horn syndrome (OHS), Indian childhood cirrhosis (ICC) and ceruloplasmin deficiency, recently discovered disorders are taken into account. These include MEDNIK syndrome, Huppke-Brendel syndrome and CCS chaperone deficiency. Another main focus is on differential diagnoses of childhood icterus correlated with age and anaemia as well as disorders of the extrapyramidal motor system. The Kayser-Fleischer ring (KFR) is qualified as classical ophthalmologic manifestation. The recently described manganese storage disease presents another rare metabolic disorder with symptoms similar to Wilson's disease. As this overview shows, Wilson's disease fits into a broad spectrum of internal and neurological disease patterns with icterus, anaemia and EPS.
Al Zohbi R, Awaida I, Farhat S, Ghandour F Cureus. 2025; 17(1):e77726.
PMID: 39974244 PMC: 11836103. DOI: 10.7759/cureus.77726.
Spectrum and classification of variants with clinical correlation in children with Wilson disease.
Al-Obaidi R, Al-Musawi B Saudi Med J. 2025; 46(2):131-142.
PMID: 39933775 PMC: 11822923. DOI: 10.15537/smj.2025.46.2.20240997.
Clinical, biochemical and molecular characterization of Wilson's disease in Moroccan patients.
Lafhal K, Sabir E, Hakmaoui A, Hammoud M, Aimrane A, Najeh S Mol Genet Metab Rep. 2023; 36:100984.
PMID: 37323222 PMC: 10267639. DOI: 10.1016/j.ymgmr.2023.100984.
Plant-derived chelators and ionophores as potential therapeutics for metabolic diseases.
Lee V, Janisse S, Heffern M Chem Soc Rev. 2023; 52(11):3927-3945.
PMID: 37203389 PMC: 10281457. DOI: 10.1039/d3cs00167a.
Guo S, Chen Z, Dong Y, Ni Y, Zhao R, Ma W Biology (Basel). 2023; 12(2).
PMID: 36829476 PMC: 9953443. DOI: 10.3390/biology12020197.